$BRVE

Cantor Fitzgerald Initiates Braveheart Bio at Overweight With $40 Price Target

TD Cowen Initiates Braveheart Bio at Buy

Jefferies Initiates Braveheart Bio at Buy With $48 Price Target

Stifel Initiates Braveheart Bio at Buy With $45 Price Target

Goldman Sachs Initiates Braveheart Bio at Buy With $48 Price Target

Braveheart Bio Insider Bought Shares Worth $499,986, According to a Recent SEC Filing

James Paul Rickey, Chief Financial Officer, on August 05, 2026, executed a purchase for 27,777 shares in Braveheart Bio (BRVE) for $499,986. Following the Form 4 filing with the SEC, Rickey has control over a total of 703,575 common shares of the company, with 520,927 shares held directly and 182,648 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2131524/000147083126000804/xslF345X05/wk-form4_1786135298.xml

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index fractionally higher and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) was up 0.4%.In corporate news, Emergent BioSolutions (EBS) shares dropped 30% after it cut its full-year guidance and announced an organizational restructuring plan.Becton, Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's Q3 results exceeded Wall Street's estimates amid revenue gains across all divisions. Its shares gained 3.5%.Enovis (ENOV) shares fell 13% after the company reported its results for fiscal Q2.Braveheart Bio (BRVE) shares surged 70% in its Nasdaq debut Thursday, after the company announced an upsized IPO of 21.25 million common shares late Wednesday.

Top Midday Gainers

ClearOne's (CLRO) majority stockholder, First Finance, has provided written consent approving the issuance of 12.5 million new common shares to Vivani Medical, a condition required to close its planned merger with Vivani unit Cortigen, the company said in a regulatory filing.Shares of ClearOne soared 157% amid a surge in intraday trading volume to over 59.7 million from a daily average of about 3.23 million.Braveheart Bio's (BRVE) unveiled an upsized initial public offering of 21.25 million common shares late Wednesday.Shares surged 66% as intraday trading volume jumped to over 1.74 million.Motorola Solutions (MSI) delivered a better-than-expected Q2, driven by continued outperformance from Silvus Technologies in defense markets and a surprise return to growth in its Land Mobile Radio business, Morgan Stanley said in a Thursday research note.Shares jumped 8.2%, with intraday trading volume rising to more than 1.06 million from the stock's daily average of about 1.13 million.Price: $9.37, Change: $+5.61, Percent Change: +149.20%

Sector Update: Healthcare Stocks Fall in Afternoon Trading

Healthcare stocks were lower Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.5%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, Enovis (ENOV) shares fell 11% after the company reported its results for fiscal Q2.Becton, Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's Q3 results exceeded Wall Street's estimates amid revenue gains across all divisions. Its shares gained 4.7%.Braveheart Bio (BRVE) shares rose 67% in its Nasdaq debut Thursday, after the company announced an upsized IPO of 21.25 million common shares late Wednesday.

Braveheart Bio Shares Rise After Market Debut

Braveheart Bio (BRVE) shares rose 69.8% in Thursday trading after the company announced an upsized initial public offering of 21.25 million common shares late Wednesday.The stock opened for trading Thursday at $30.20, compared with its public offering price of $18 per share.The offering is expected to close Friday, subject to customary closing conditions.Price: $30.53, Change: $+12.53, Percent Change: +69.58%